News Release 2008

December 24, 2008Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
October 1, 2008Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
September 30, 2008Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
August 20, 2008Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
April 22, 2008Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan
April 18, 2008Launch of KIPRES Tablets 5mg
March 3, 2008Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
February 21, 2008Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
January 30, 2008Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
January 25, 2008KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis